Drug intelligence / Profile preview

Contisor

Development stage: Unknown
Lead developer: Fremed Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Contisor is a generic cardiovascular medication containing bisoprolol fumarate, a selective beta-1 adrenergic receptor antagonist. Developed and manufactured by Fremed Pharmaceutical Joint Stock Company in Vietnam, it is primarily used to treat hypertension, heart failure, and other cardiac conditions. As a beta-blocker, it works by reducing the heart rate and the heart's workload, thereby lowering blood pressure and improving cardiac efficiency. It is available in multiple strengths (2.5 mg, 5 mg, and 10 mg) and is produced in a WHO-GMP certified facility.

Brand names: ContisorContisor 2.5Contisor2.5Contisor-2.5Contisor 5Contisor5Contisor-5Contisor 10Contisor10Contisor-10
Other names: bisoprolol fumarate

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on Contisor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Contisor.

Explore the full profile